Difference between revisions of "Oxaliplatin (Eloxatin)"
Warner-admin (talk | contribs) m (Text replacement - "Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)" to "Chronic lymphocytic leukemia (CLL/SLL)") |
m |
||
| Line 30: | Line 30: | ||
==Also known as== | ==Also known as== | ||
| − | Dacotin, Dacplat, Eloxatin, Eloxatine, | + | *'''Code names:''' JM-83, RP-54780, SR-96669 |
| + | *'''Brand names:''' Coxatin, Curaplat, Cure-X, Dacotin, Dacplat, Eloplat, Eloxatin, Eloxatine, Oplatin, OxaLitin, Oxiplat, Oxitan, Oxzucia, Sibatin, Xaloplat, Xylotin, X-Plat, Zildox | ||
==References== | ==References== | ||
| Line 36: | Line 37: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
[[Category:Platinum agents]] | [[Category:Platinum agents]] | ||
Revision as of 23:58, 29 November 2017
General information
Class/mechanism: Platinum analog, alkylating-like, which produces interstrand and intrastrand DNA crosslinks that inhibit DNA replication and transcription, causing non-cell cycle specific cytotoxicity and death.[1][2][3]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic lymphocytic leukemia (CLL/SLL)
- Colon cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Extranodal NK/T-cell lymphoma, nasal type
- Hepatobiliary cancer
- Marginal zone lymphoma
- Pancreatic cancer
- Rectal cancer
- Testicular cancer
- Transformed lymphoma
Patient drug information
- Oxaliplatin (Eloxatin) package insert PDF pages 15-16[1]
- Oxaliplatin (Eloxatin) patient drug information (Chemocare)[4]
- Oxaliplatin (Eloxatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 8/9/2002: Initial FDA approval: "used in combination with infusional 5-FU/ LV, is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/ LV and irinotecan."
- 1/9/2004: Indication revised: "used in combination with infusional 5-FU/ LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.
- 11/4/2004: New indication: "used in combination with infusional 5-FU/ LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Also known as
- Code names: JM-83, RP-54780, SR-96669
- Brand names: Coxatin, Curaplat, Cure-X, Dacotin, Dacplat, Eloplat, Eloxatin, Eloxatine, Oplatin, OxaLitin, Oxiplat, Oxitan, Oxzucia, Sibatin, Xaloplat, Xylotin, X-Plat, Zildox
References
- Drug index
- Intravenous medications
- Platinum agents
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Colon cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Hepatobiliary cancer medications
- Marginal zone lymphoma medications
- Pancreatic cancer medications
- Rectal cancer medications
- Testicular cancer medications
- Transformed lymphoma medications
- Drugs FDA approved in 2002
- WHO Essential Cancer Medicine